Protalix BioTherapeutics Preparing for Financial Results Announcement
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins, is gearing up to announce its financial results for the quarter ending September 30, 2025. This announcement is a key moment for the company as it reflects ongoing progress and operational updates.
The company will share these results and insights during a conference call scheduled for November 13, 2025. This call represents an opportunity for investors and stakeholders to gauge the company’s performance and strategic direction in a rapidly evolving sector.
Details of the Upcoming Conference Call
The upcoming conference call at 8:00 a.m. Eastern Standard Time (EST) will allow management to delve into the financial outcomes and showcase recent developments within Protalix. Participants can expect a comprehensive update that articulates the company’s path forward.
Accessing the Conference Call
For those wishing to participate directly in the call, a toll-free number will be available: 1-877-423-9813 for domestic calls and 1-201-689-8573 for international participants. Additionally, an Israeli toll-free number is provided: 1-809-406-247. The conference ID is 13757080.
To ensure a seamless experience, participants are encouraged to connect at least 15 minutes prior to the scheduled start to manage any audio software needs. For those unable to attend, a replay of the call will be accessible for a limited time, showcasing Protalix's commitment to transparency with its stakeholders.
Webcast and Additional Resources
The conference call will also be accessible via a live webcast. Protalix is committed to providing additional resources and insights through its website. Participants can visit the company’s investor relations section for links and further details.
About Protalix BioTherapeutics
Protalix is at the forefront of biopharmaceutical innovation, focusing on the development of recombinant therapeutic proteins. The company distinguishes itself by employing the ProCellEx® plant cell-based protein expression system, which has allowed Protalix to achieve FDA approval for its products.
One of the pivotal products developed through this unique system is taliglucerase alfa, a treatment option for Gaucher disease. Protalix has established a partnership with Pfizer Inc. for the worldwide rights to commercialize this significant therapy. The company has also introduced Elfabrio®, which received regulatory approvals from the FDA and the European Medicines Agency in May 2023.
Protalix further demonstrates its innovative spirit through collaborations with organizations like Chiesi Farmaceutici S.p.A., aimed at advancing the global development of Elfabrio.
Exploring Protalix’s Development Pipeline
Protalix is actively developing a robust pipeline of recombinant therapeutic proteins tailored to address high-demand pharmaceutical markets. Notable candidates in this pipeline include PRX–115, targeting uncontrolled gout, and PRX–119, which aims to provide innovative solutions for NETs-related diseases. These products underscore the company’s dedication to addressing significant health challenges using its unique expression technology.
Investor Relations and Contact Information
For investors and those interested in learning more about the upcoming announcement, Mike Moyer, Managing Director at LifeSci Advisors, serves as the primary contact. He can be reached at +1-617-308-4306 for further inquiries. Protalix values open communication and encourages stakeholders to reach out with questions or to seek additional information about the company’s developments.
Frequently Asked Questions
What is Protalix BioTherapeutics known for?
Protalix focuses on developing and commercializing recombinant therapeutic proteins through its proprietary plant-based expression system.
When will the Q3 financial results announcement take place?
The financial results are set to be announced on November 13, 2025, during a conference call.
How can I participate in the conference call?
Participants can call 1-877-423-9813 for domestic calls and 1-201-689-8573 for international access, using conference ID 13757080.
What products have Protalix developed?
Protalix has developed products like taliglucerase alfa for Gaucher disease and Elfabrio®, which has achieved regulatory approval in the U.S. and Europe.
Who can I contact for investor relations?
Investors can reach Mike Moyer at LifeSci Advisors by calling +1-617-308-4306 for inquiries regarding the company.
